FDA Filing of Alzheimer’s Therapy Aducanumab Delayed to Late 2020, Biogen Says

Biogen is pushing back the submission of aducanumab, its investigational treatment for Alzheimer’s disease, to the U.S. Food and Drug Administration (FDA) to the third quarter of this year due to the COVID-19 pandemic, the company announced. “The COVID-19 pandemic has created a challenging situation for people and companies throughout the world, and Biogen personally felt the painful impact of this global crisis,” Michel Vounatsos, Biogen’s CEO, said in a company report. “Outside the U.S.,…

You must be logged in to read/download the full post.